CN107001456A - 抗ang2 抗体及使用方法 - Google Patents

抗ang2 抗体及使用方法 Download PDF

Info

Publication number
CN107001456A
CN107001456A CN201580060787.3A CN201580060787A CN107001456A CN 107001456 A CN107001456 A CN 107001456A CN 201580060787 A CN201580060787 A CN 201580060787A CN 107001456 A CN107001456 A CN 107001456A
Authority
CN
China
Prior art keywords
antibody
amino acid
seq
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580060787.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·登勒
G·乔治斯
P·M·许尔斯曼
H·克腾伯格
J·莫莱肯
M·莫尔霍伊
J·T·雷古拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107001456A publication Critical patent/CN107001456A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580060787.3A 2014-11-10 2015-11-06 抗ang2 抗体及使用方法 Pending CN107001456A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192524 2014-11-10
EP14192524.8 2014-11-10
PCT/EP2015/075876 WO2016075035A1 (en) 2014-11-10 2015-11-06 Anti-ang2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
CN107001456A true CN107001456A (zh) 2017-08-01

Family

ID=51868115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580060787.3A Pending CN107001456A (zh) 2014-11-10 2015-11-06 抗ang2 抗体及使用方法

Country Status (14)

Country Link
US (1) US10538585B2 (2)
EP (1) EP3218398A1 (2)
JP (2) JP2017534644A (2)
KR (1) KR20170082594A (2)
CN (1) CN107001456A (2)
AR (1) AR102595A1 (2)
AU (1) AU2015345321A1 (2)
BR (1) BR112017009790A2 (2)
CA (1) CA2963606A1 (2)
IL (1) IL251477A0 (2)
MX (1) MX2017005642A (2)
SG (1) SG11201703458UA (2)
TW (1) TW201630935A (2)
WO (1) WO2016075035A1 (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491951A (zh) * 2017-12-22 2020-08-04 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
CN115772544A (zh) * 2021-09-06 2023-03-10 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN116925234A (zh) * 2022-04-02 2023-10-24 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
WO2024066377A1 (zh) * 2022-09-28 2024-04-04 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
JP2023530187A (ja) 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
US20230312698A1 (en) * 2020-08-07 2023-10-05 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
CN116209765B (zh) * 2020-08-19 2025-11-07 药物抗体公司 经修饰抗体及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374522A (zh) * 2006-01-27 2009-02-25 安姆根有限公司 Ang2和vegf抑制剂的组合
WO2010040508A1 (en) * 2008-10-08 2010-04-15 F. Hoffmann-La Roche Ag Bispecific anti-vegf/anti-ang-2 antibodies
CN102046657A (zh) * 2008-02-20 2011-05-04 安姆根有限公司 针对血管生成素-1和血管生成素-2的抗体及其用途
CN102257008A (zh) * 2008-12-16 2011-11-23 霍夫曼-拉罗奇有限公司 针对人血管生成素2的抗体
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014177460A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP1481010A2 (en) 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
EP1590369B1 (en) 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2398693T3 (es) 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
MX358726B (es) * 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CN104661679A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合
JP2015532272A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
HK1216428A1 (zh) 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
KR20160085888A (ko) * 2013-12-20 2016-07-18 에프. 호프만-라 로슈 아게 항-ang2 항체 및 cd40 작용제를 사용한 조합 요법
RU2727639C2 (ru) * 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
AU2015345323A1 (en) * 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
WO2016209972A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
MX2019014199A (es) * 2017-06-02 2020-01-23 Boehringer Ingelheim Int Tratamiento de combinacion antineoplasico.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374522A (zh) * 2006-01-27 2009-02-25 安姆根有限公司 Ang2和vegf抑制剂的组合
CN102046657A (zh) * 2008-02-20 2011-05-04 安姆根有限公司 针对血管生成素-1和血管生成素-2的抗体及其用途
WO2010040508A1 (en) * 2008-10-08 2010-04-15 F. Hoffmann-La Roche Ag Bispecific anti-vegf/anti-ang-2 antibodies
CN102257008A (zh) * 2008-12-16 2011-11-23 霍夫曼-拉罗奇有限公司 针对人血管生成素2的抗体
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014177460A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KYRIAKOS P. PAPADOPOULOS等: ""A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb),in patients with advanced solid tumor malignancies."", 《JOURNAL OF CLINICAL ONCOLOGY》 *
MARKUS THOMAS等: ""A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors"", 《PLOS ONE》 *
SEBASTIAN FENN等: ""Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain"", 《PLOS ONE》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491951A (zh) * 2017-12-22 2020-08-04 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
CN111491951B (zh) * 2017-12-22 2024-05-24 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
CN115772544A (zh) * 2021-09-06 2023-03-10 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN115772544B (zh) * 2021-09-06 2024-04-26 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN116925234A (zh) * 2022-04-02 2023-10-24 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
WO2024066377A1 (zh) * 2022-09-28 2024-04-04 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用

Also Published As

Publication number Publication date
JP2021050229A (ja) 2021-04-01
US10538585B2 (en) 2020-01-21
SG11201703458UA (en) 2017-05-30
AR102595A1 (es) 2017-03-08
WO2016075035A1 (en) 2016-05-19
US20170247441A1 (en) 2017-08-31
MX2017005642A (es) 2017-07-24
JP2017534644A (ja) 2017-11-24
TW201630935A (zh) 2016-09-01
BR112017009790A2 (pt) 2017-12-19
IL251477A0 (en) 2017-05-29
AU2015345321A1 (en) 2017-04-20
KR20170082594A (ko) 2017-07-14
CA2963606A1 (en) 2016-05-19
EP3218398A1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
US10538585B2 (en) Anti-ANG2 antibodies and methods of use
JP6695812B2 (ja) Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
CN107148429B (zh) 抗-pdgf-b抗体和使用方法
US10626177B2 (en) HER3 antigen binding proteins binding to the beta-hairpin of HER3
JP6537970B2 (ja) Ｈｅｒ３のベータヘアピン及びｈｅｒ４のベータヘアピンに結合する抗ｈｅｒ３／ｈｅｒ４抗原結合タンパク質
CN107074941A (zh) 双特异性抗体和用于眼科学的方法
CN105164157A (zh) Fc-受体结合的修饰的非对称抗体及使用方法
CN107074942A (zh) 抗‑IL‑1β抗体和使用方法
CN115916826A (zh) 与CD3和FolR1结合的抗体
JP6433511B2 (ja) Ｈｅｒ３のベータヘアピンに結合する抗ｈｅｒ３抗体
CN106459197A (zh) 结合HER1 β‑发夹的HER1抗原结合蛋白
HK1241384A1 (en) Anti-ang2 antibodies and methods of use
HK1239711B (zh) 抗-pdgf-b抗体和使用方法
HK1239711A1 (en) Anti-pdgf-b antibodies and methods of use
HK1236207A1 (en) Bispecific antibodies and methods of use in ophthalmology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241384

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1241384

Country of ref document: HK